Anti-tumor Antibodies Can Drive Therapeutic T Cell Responses
Name
nihms892691.pdf
Description
Accepted version
Size
621.08 KB
Format
Unknown
Checksum (MD5)
d527230abf728cac567a56d0c5d8d2a5
Author(s)
Wittrup, Karl Dane
Date Issued
2017
Journal
Trends in Cancer
Publisher
Elsevier BV
Version
Author's final manuscript
Abstract
© 2017 Elsevier Inc. The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of profoundly synergizing with T cell-directed immunotherapies such as checkpoint blockade and adoptive cell therapy. Two key components account for this synergy: (i) a self-vaccinal effect mediated by dendritic cells (DCs); and (ii) an inflammatory repolarization of the tumor microenvironment. Efficient exploitation of these mechanisms has tremendous therapeutic potential.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.TRECAN.2017.07.001
